CD274 and neoplasm: Based on phase I study data (KEYNOTE-001), which showed more efficacy of pembrolizumab with higher PD-L1 expression and 50% as cut off related to an increase in ORR, PFS, and OS [35], a randomized phase II/III trial was performed on 1034 patients, with PD-L1 at least on 1% of tumor cells as inclusion criterion (KEYNOTE-010).